Last reviewed · How we verify
NCT07380737
Feasibility and Preliminary Effects of the Walking Tall App for Home-Based Gait Training in Parkinson's Disease: A Pilot Study
NA trial testing Walking Tall App in Parkinson's Disease in 30 participants. Currently enrolling.
31 August 2026
Quick facts
| Lead sponsor | Tel-Aviv Sourasky Medical Center |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 29 December 2025 |
| Primary completion | 31 August 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Walking Tall App
Conditions studied
- Parkinson's Disease — all drugs for Parkinson's Disease →
Sponsor
Tel-Aviv Sourasky Medical Center
Who can join
Adults 40 to 85, any sex, with Parkinson's Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a pilot study designed to assess the feasibility, adherence, and preliminary effects of a 6-week home-based gait training intervention using the Walking Tall mobile app in individuals with Parkinson's disease. The app delivers rhythmic auditory cues and motivational verbal prompts to promote gait improvements. Primary outcomes include daily walking duration and step count measured via wearable sensors; secondary outcomes include gait speed, balance, self-reported confidence, and usability.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07380737
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Parkinson's Disease
Currently open trials in the same condition.
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07330258 — A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite · recruiting
- NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
- NCT07384442 — Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's · NA · recruiting
- NCT06562569 — Non-invasive VNS for PD Gait · NA · recruiting
Other Tel-Aviv Sourasky Medical Center trials
Trials by the same sponsor.
- NCT07104136 — Improving Adherence to COPD Treatments in Primary Care · NA · enrolling by invitation
- NCT07327021 — MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC · Phase 2 · recruiting
- NCT07191249 — A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previousl · Phase 2 · not yet recruiting
- NCT07235332 — Assessing Toxic Metal Exposure From Vegetarian/Vegan, Omnivorous, and Low-carb Diets in Israel. · enrolling by invitation
- NCT06966869 — Evaluation of Fentanyl Transdermal Patch Absorption in Hemodynamically Unstable ICU Patients. · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07380737 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tel-Aviv Sourasky Medical Center
- Last refreshed: 13 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07380737.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing